Contributor Page
Ropes & Gray LLP
 
Email  |  Website  |  Articles
Contact Details
Tel: +1 212 5969000
Fax: +1 212 5969090
1211 Avenue of the Americas
New York
New York
NY 10036-8704
United States
Awards
By Ropes & Gray LLP's Securities & Public Companies Practice
On October 11, 2017, at the first open meeting under Chairman Jay Clayton's tenure, the SEC proposed amendments to modernize and simplify certain disclosure requirements in Regulation S-K.
By Ropes & Gray LLP's Health Care Practice
California is one of several states to have recently enacted drug pricing laws in response to growing debate over prescription drug costs.
By Marc Berger, Helen Gugel
Two months after warning investors that some digital tokens or coins may qualify as securities under the federal securities laws, the SEC on September 29, 2017 brought its first enforcement action...
By Alison Fethke, Devin Cohen, Haley N. Bavasi, Charles O'Toole
Given the uptick in global awareness and enforcement of anti-bribery and corruption laws, most U.S.-based health care companies are attuned to the risks associated with legal infractions...
By Marc Berger, Helen Gugel
Two months after warning investors that some digital tokens or coins may qualify as securities under the federal securities laws, the SEC on September 29, 2017 brought its first enforcement action in connection with an ICO.
By Leslie Spencer, Marta Belcher
Blockchain — the distributed ledger technology underlying bitcoin — has the potential to have a revolutionary impact far beyond cryptocurrencies.
By Ropes & Gray LLP's Government Enforcement/White Collar Crime Practice, Ropes & Gray LLP's China Life Sciences
In August 2017, multiple departments of Shanghai government, led by Shanghai's Health and Family Planning Commission, jointly issued a series of administrative rules to tighten the interactions...
By Ropes & Gray LLP's Investment Management Practice Group
The following summarizes recent legal developments of note affecting the mutual fund/investment management industry:
By Keith Higgins
On Friday, October 6, the Treasury Department issued a report to the President on streamlining and reforming U.S. capital market regulation.
By Brendan Hanifin, Emerson Siegle, Sean Seelinger
It is too early to assess whether the revocation of the SSR will mark a significant turning point away from broad country-based sanctions.
By Katherine Wang
In addition, the Final Policy attempts to strike a balance between the potentially conflicting interest of innovative and generic drug manufacturers.
By Scott A. McKeown
Yesterday I explained why In re Aqua Products would not result in PTAB Motions to Amend being any more attractive or ultimately successful.
By Thomas N. Bulleit, Jessica M. Band
In light of the skepticism expressed by the now-former U.S. Department of Health and Human Services Secretary Tom Price toward much of the Obama administration's approach to mandatory bundled payment initiatives, ...
By Ropes & Gray LLP's Health Care Practice
Given the uptick in global awareness and enforcement of anti-bribery and corruption laws, most health care companies are attuned to the risks associated with legal infractions caused by ex-U.S. activities.
By Scott A. McKeown
For PTAB practitioners, the en banc decision in In re Aqua Products is a complete non-event. While the decision has been embraced as a net positive for Patentees, practically speaking...
Contributor's Topics
More...